**Supporting Information – Table S2**

**Pentacyclic nitrofurans with *in vivo* efficacy and activity against latent *Mycobacterium tuberculosis***

Rakesh,1† David F. Bruhn,1† Michael S. Scherman,2 Lisa K. Woolhiser,2 Dora B. Madhura,3 Marcus M. Maddox,1 Aman P. Singh,1,4 Robin B. Lee,1 Julian G. Hurdle,1‡ Michael R. McNeil,2 Anne J. Lenaerts,2 Bernd Meibohm,3 Richard E. Lee1,4\*

1 Department of Chemical Biology and Therapeutics, St. Jude Children’s Research Hospital, Memphis, TN, USA

2 Mycobacterial Research Laboratories, Department of Microbiology, Colorado State University, Fort Collins, CO, USA

3 Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA

4 Biomedical Sciences Program, Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, TN, USA

‡ Present address: Department of Biology, University of Texas Arlington, Arlington, TX, USA  
\* [Richard.Lee@StJude.org](mailto:Richard.Lee@StJude.org) to whom all correspondence should be addressed.

† These authors contributed equally.

**Table S2: Assessment of Efficacy in an *in vivo* Murine Model of Acute Tuberculosis Infection**

1. Bacterial Load and Reduction in Lungs

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Treatment Group** | **Log10CFU (SEM)** | **Log10CFU Reduction (SEM)** | **P Value** | **Statistically Significant?** |
| Untreated | 8.07 (0.21) | - | - | - |
| 1 | 7.01 (0.11) | 1.06 (0.18) | < 0.05 | yes |
| 2 | 6.77 (0.14) | 1.30 (0.20) | < 0.05 | yes |
| 3 | 6.61 (0.11) | 1.47 (0.18) | < 0.05 | yes |
| 4 | 6.69 (0.07) | 1.38 (0.16) | < 0.05 | yes |
| 5 | 6.99 (0.06) | 1.08 (0.15) | < 0.05 | yes |
| 6 | 6.99 (0.15) | 1.10 (0.21) | < 0.05 | yes |
| 7 | 4.60 (0.21) | 3.47 (0.21) | < 0.05 | yes |

1. Bacterial Load and Reduction in Spleen

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Treatment Group** | **Log10CFU (SEM)** | **Log10CFU Reduction (SEM)** | **P Value** | **Statistically Significant?** |
| Untreated | 7.20 (0.14) | - | - | - |
| 1 | 6.25 (0.11) | 0.95 (0.18) | < 0.01 | yes |
| 2 | 5.72 (0.09) | 1.48 (0.17) | < 0.001 | yes |
| 3 | 5.43 (0.23) | 1.77 (0.27) | < 0.001 | yes |
| 4 | 6.03 (0.12) | 1.17 (0.18) | < 0.001 | yes |
| 5 | 5.76 (0.08) | 1.44 (0.16) | < 0.001 | yes |
| 6 | 6.17 (0.14) | 1.03 (0.20) | < 0.001 | yes |
| 7 | 2.61 (0.09) | 4.59 (0.16) | < 0.001 | yes |

CFU in organs indicated were enumerated plating serial dilutions of organ homogenate. Log10 protection was calculated by subtracting bacterial titer of each treatment from that of the untreated control. Mice were treated with 300 mg/kg QD with compounds **9a** dissolved in **(1)** 0.5% methylcellulose in DI-H2O **(2)** 30% Captisol in DI-H2O **(3)** 10% Vitamin E TPGS in DI-H2O **(4)** 0.5% Tween 80 in DI-H2O **(5)** 20% cyclodextrin in DI-H2O or **(6)** cold PEG (50:35:15 H2O:PEG300:PG) or (**7**) isoniazid dissolved in water. Error bars indicate SEM within treatment groups of 5-7 mice per group. Statistical significance was calculated by Tukeys’s multiple comparison test.